DE3682208D1 - Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung. - Google Patents

Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.

Info

Publication number
DE3682208D1
DE3682208D1 DE8686117660T DE3682208T DE3682208D1 DE 3682208 D1 DE3682208 D1 DE 3682208D1 DE 8686117660 T DE8686117660 T DE 8686117660T DE 3682208 T DE3682208 T DE 3682208T DE 3682208 D1 DE3682208 D1 DE 3682208D1
Authority
DE
Germany
Prior art keywords
nifedipine
stabilized
influence
production
light
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686117660T
Other languages
German (de)
English (en)
Inventor
Kurt Heinz Bauer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Application granted granted Critical
Publication of DE3682208D1 publication Critical patent/DE3682208D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE8686117660T 1986-12-18 1986-12-18 Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung. Expired - Lifetime DE3682208D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP86117660A EP0272336B1 (de) 1986-12-18 1986-12-18 Gegenüber Lichteinfluss stabilisiertes Nifedipin-Konzentrat und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
DE3682208D1 true DE3682208D1 (de) 1991-11-28

Family

ID=8195654

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686117660T Expired - Lifetime DE3682208D1 (de) 1986-12-18 1986-12-18 Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.

Country Status (7)

Country Link
US (1) US4904699A (en:Method)
EP (1) EP0272336B1 (en:Method)
JP (1) JPS63165318A (en:Method)
AT (1) ATE68704T1 (en:Method)
DE (1) DE3682208D1 (en:Method)
ES (1) ES2040697T3 (en:Method)
GR (1) GR3003631T3 (en:Method)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3738236A1 (de) * 1987-11-11 1989-05-24 Euro Celtique Sa Beisskapsel
HUT59592A (en) * 1990-07-20 1992-06-29 Egyt Gyogyszervegyeszeti Gyar Process for the preparation of solid medical products
US5145859A (en) * 1991-03-20 1992-09-08 Case Western Reserve University Methods of treating interstitial cystitis and urethral syndrome
US5229130A (en) * 1991-12-20 1993-07-20 Cygnus Therapeutics Systems Vegetable oil-based skin permeation enhancer compositions, and associated methods and systems
BE1006990A5 (nl) * 1993-04-22 1995-02-07 Univ Gent Werkwijze en samenstelling om een aktief bestanddeel in een vaste toedieningsvorm te brengen.
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US6726930B1 (en) * 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
AU695734B2 (en) 1996-07-08 1998-08-20 Penwest Pharmaceuticals Co. Sustained release matrix for high-dose insoluble drugs
IN186245B (en:Method) 1997-09-19 2001-07-14 Ranbaxy Lab Ltd
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
US6168806B1 (en) 1999-03-05 2001-01-02 Fang-Yu Lee Orally administrable nifedipine pellet and process for the preparation thereof
DE19913692A1 (de) * 1999-03-25 2000-09-28 Basf Ag Mechanisch stabile pharmazeutische Darreichungsformen, enthaltend flüssige oder halbfeste oberflächenaktive Substanzen
JP3893058B2 (ja) * 1999-09-30 2007-03-14 ペンウェスト ファーマシューティカルズ カンパニー 高度に可溶性の薬物のための徐放性マトリックス系
JP5767429B2 (ja) * 1999-11-12 2015-08-19 アッヴィ・インコーポレイテッド 固体分散剤中の結晶化阻害剤
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US20040247689A1 (en) * 2003-03-26 2004-12-09 Guy Samburski Process for preparing a pharmaceutical active ingredient with high specific surface area
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) * 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
WO2008067164A2 (en) * 2006-11-15 2008-06-05 Abbott Laboratories Solid pharmaceutical dosage formulations
GB0703514D0 (en) * 2007-02-23 2007-04-04 Univ Ulster Use of riboflavin
SG11201404419WA (en) * 2012-02-16 2014-10-30 Teva Pharma N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinoline carboxamide, preparation and uses thereof
CA2968861C (en) 2017-05-30 2022-10-11 University Of Saskatchewan Topical nifedipine formulations and uses thereof
EP3876912B1 (en) 2018-11-07 2023-04-19 DSM IP Assets B.V. Medicaments containing riboflavin exhibiting improved flowability

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU432703A3 (en:Method) * 1971-08-24 1974-06-15 Фридрих Боссерт, Вульф Фатер, Курт Бауер
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
GB2111978B (en) * 1981-10-19 1985-05-01 Maruko Pharmaceutical Co 1 4-dihydropyridine compounds
DE3339236A1 (de) * 1983-10-28 1985-05-09 Bayer Ag Arzneimittelzubereitung
DE3438830A1 (de) * 1984-10-23 1986-04-30 Rentschler Arzneimittel Nifedipin enthaltende darreichungsform und verfahren zu ihrer herstellung
DE3532129A1 (de) * 1985-09-10 1987-03-12 Bayer Ag Ss-carotin enthaltende gelatine

Also Published As

Publication number Publication date
ATE68704T1 (de) 1991-11-15
US4904699A (en) 1990-02-27
ES2040697T3 (es) 1993-11-01
EP0272336B1 (de) 1991-10-23
JPS63165318A (ja) 1988-07-08
GR3003631T3 (en:Method) 1993-03-16
EP0272336A1 (de) 1988-06-29

Similar Documents

Publication Publication Date Title
DE3682208D1 (de) Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.
ATE201328T1 (de) Hochkonzentriertes immunglobulin-präparat und verfahren zu seiner herstellung
DE3577552D1 (de) Vitamin d-derivate und verfahren zu deren herstellung.
DE3785163D1 (de) 3-pyrrolidinylthio-1-azabicyclo(3.2.0)hept-2-en-2-carbonsaeurederivate und verfahren zu deren herstellung.
DE3766878D1 (de) Prothesenteil sowie verfahren zu seiner herstellung.
DE3764828D1 (de) Derivate von n-alpha-arylsulfonylaminoacyl-p-amidino-phenylalaninamiden, verfahren zu deren herstellung, deren verwendung als arzneimittel und deren zwischenverbindungen.
DE3586436D1 (de) Kosmetische emulsion und verfahren zu deren herstellung.
DE3581328D1 (de) Derivate des menschlichen alpha-1-antitrypins und verfahren zu deren herstellung.
DE3481997D1 (de) Verfahren zur herstellung optisch aktiver aryloxypropionsaeuren und deren als herbizide verwendbare derivate.
DE69001573D1 (de) Zusammensetzungen zur herstellung von in dosisformen aktiven vitaminen d3 sowie verfahren zur herstellung stabiler, in dosisformen aktiver vitamine d3 unter deren verwendung.
DE3884870D1 (de) Verfahren zur Herstellung von Vitamin-D-Derivaten.
DE69427955D1 (de) Verfahren zur Herstellung von 2,2-Difluorketensilylacetalen und alpha,alpha-Difluor-beta -Silyloxy-1,3-Dioxolan-4-Propansäureestern
DE3677401D1 (de) Verfahren zur herstellung von perylen-3,4,9,10-tetracarbonsaeurearylimiden.
DE3678624D1 (de) Halbleiter-lawinenphotodetektor und verfahren zur herstellung.
ATE121420T1 (de) Verfahren zur herstellung von 3-(l-pyroglutamyl)- l-thiazolidin-4-carbonsäure-derivaten.
DE58905079D1 (de) Neue alpha-aminocarbonsaeure-derivate, ihre herstellung und verwendung.
ATE106887T1 (de) Ester der 10-(1-hydroxy-äthyl)-11-oxo-1- azatricyclo(7.2.0.0(3,8)>undec-2-ene-2- carbonsäure und deren derivate und verfahren zu ihrer herstellung.
DE3577443D1 (de) Derivate von dihydroorotsaeure, deren verfahren zur herstellung und deren pharmazeutische zusammensetzungen.
DE3774542D1 (de) Halbleiterlaser und verfahren zu seiner herstellung.
DE3772403D1 (de) Zitronensaeurederivate als emulgatoren fuer die emulsationspolymerisation.
ATE63920T1 (de) Neue n-glycosylamidderivate, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel.
DE3770752D1 (de) 5-pyrazolon-derivate, verfahren zu deren herstellung, deren anwendung als herbizide und deren zusammensetzungen.
ATE136299T1 (de) Verfahren zur herstellung der racemischen und optisch aktiven 1,2,3,4-tetrahydroisochinolin-3- carbonsäure sowie deren vorprodukte
DE3851979D1 (de) Substituierte Vinylcephalosporine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel.
DE3863136D1 (de) Derivate des 2,2-bis-(3-aminophenyl)-hexafluorpropans und verfahren zur herstellung des 2,2-bis-(3,4-diaminophenyl)-hexafluorpropans.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee